About
Corporate Overview
Management Team
Board of Directors
Partnerships
Product Candidates
Pipeline
Tivozanib
Ficlatuzumab
AV
-203
AV
-380
AV
-353
Publications & Presentations
Media
Press Releases
Media Toolkit
Investors
Overview
Corporate Governance
Stock Information
Research Coverage
SEC Filings
Annual Reports
Press Releases
Scientific Publications & Presentations
Calendar of Events
FAQs
Information Request
Careers
Life at AVEO
Job Openings
Contact
click
passionately pursuing a better life for patients with cancer.
follow our pursuit
latest news
Nov 10 | 2020
AVEO Oncology to Present at the Stifel 2020 Virtual Healthcare Conference
read more »
TIVO-3 ASCO 2020 Poster
ASCO 2020 TIVO-3 Presentation
Click
Here
To View Our ASCO Poster:
TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)
###
About
Corporate Overview
Management Team
Board of Directors
Partnerships
Product Candidates
Pipeline
Tivozanib
Ficlatuzumab
AV
-203
AV
-380
AV
-353
Publications & Presentations
Media
Press Releases
Media Toolkit
Investors
Overview
Corporate Governance
Stock Information
Research Coverage
SEC Filings
Annual Reports
Press Releases
Scientific Publications & Presentations
Calendar of Events
FAQs
Information Request
Careers
Life at AVEO
Job Openings
Contact
